<DOC>
	<DOCNO>NCT00707954</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics pharmacodynamics TA-7284 orally administer daily 15 day ( 1 day follow 1 day washout period 14 consecutive day ) . Dose escalation design utilized study , dose escalation TA-7284 start 25 mg ( step 1 ) . Subsequent dose 100 mg ( step 2 ) , 200 mg ( step 3 ) 400 mg ( step 4 ) plan review tolerance PK previous step .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics TA-7284 Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Clinically stable Type 2 Diabetes Mellitus Females without childbearing potential Body mass index ( BMI ) &gt; = 18.5 kg/m2 &lt; = 39.9 kg/m2 Hemoglobin A1c level &gt; = 6.5 % &lt; = 10 % Fasting blood glucose level &gt; = 140 mg/dL &lt; = 270 mg/dL Systolic blood pressure &gt; = 95 mmHg &lt; = 160 mmHg , diastolic blood pressure &gt; = 50 mmHg &lt; = 100 mmHg , pulse rate &gt; = 50 bpm Patients administer antidiabetic medication within 2 week Prior dose Medicines necessary Hypertension Dyslipidemia administer stable dosage least 3 month Treatment diet exercise unchanged 3 month Type 1 Diabetes Mellitus Secondary Diabetic Mellitus History diabetic complication need treatment Treatment insulin , thiazolidinediones , thiazide diuretics„ÄÅbeta blocker systemic steroid within 3 month prior inform consent Serum creatinine &gt; upper limit normal range Patients significant complication</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>TA-7284</keyword>
</DOC>